Evidence map›Paper›PMID 40365025›Full record

ArticleIJTLD open2025

Evaluating disability, comorbidities and risk factors after TB treatment: an 18-24 month follow-up.

Y Sun, Y Lin, J E Golub, W Shu, J Jiang, Q Xu, Y Li, W Sun, Y Shi, J Liao and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Y SunClinical Center on TB, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
Y LinInternational Union Against Tuberculosis and Lung Disease, Paris, France.
J E GolubJohns Hopkins Centre for Tuberculosis, Johns Hopkins University School of Medicine, Baltimore, USA.
W ShuClinical Center on TB, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
J JiangThe Third People's Hospital of Yichang City, Yichang, Hubei 443000, China.
Q XuWuhan Pulmonary Hospital, Wuhan, Hubei 430030, China.
Y LiThe First People's Hospital of Yongkang, Jinhua, Zhejiang 321300, China.
W SunEzhou Third Hospital, Ezhou, Hubei 436000, China.
Y ShiDongyang People's Hospital, Dongyang, Zhejiang 322100, China.
J LiaoThe People's Hospital of Laibin, Laibin, Guangxi 546100, China.
C NieXiangyang Institute of Tuberculosis Control and Prevention, Xiangyang, Hubei 441000.
C LiangBaise City People's Hospital, Baise, Guangxi 533000, China.
X ZhangZhongwei People's Hospital, Zhongwei, Ningxia 755000, China.
H LiuGuangxi Chest Hospital, Liuzhou, Guangxi 545000, China.
Y MaThe People's Hospital of Tongxin, Wuzhong, Ningxia 751100, China.
R ZachariahTDR, Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland.
S D BergerInternational Union Against Tuberculosis and Lung Disease, Paris, France.
P ThekkurInternational Union Against Tuberculosis and Lung Disease, Paris, France.
D NairInternational Union Against Tuberculosis and Lung Disease, Paris, France.
S SatyanarayanaInternational Union Against Tuberculosis and Lung Disease, Paris, France.
A M V KumarInternational Union Against Tuberculosis and Lung Disease, Paris, France.
A D HarriesInternational Union Against Tuberculosis and Lung Disease, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral countries have developed national strategic plans to address post-TB disability and comorbidities. However, their feasibility and added value within routine programmatic settings remain undocumented.

methodsWe followed up individuals who successfully completed TB treatment at 11 health facilities in China between 2022-2023. Within the programmatic setting, we assessed health status, on-going symptoms, comorbidities, risk factors and disability (measured by 6-minute walking test [6MWT]) 18-24 months after treatment completion.

resultsOf 586 individuals who completed TB treatment, 503 (86%) were reassessed. Compared with end of TB treatment, there were significant increases in cough (11.0% versus 6.4%), untreated diabetes (3.2% versus <1.0%), high blood pressure (13.1% versus 8.9%), cigarette smoking (12.7% versus 5.2%) and excessive alcohol consumption (5.8% versus 1.2%). Other conditions remained similar with 27.0% still disabled (6MWT<400m). 78 (13%) patients died or were lost-to-follow-up, with risk factors at end of treatment including on-going symptoms (RR1.7, 95%CI 1.1-2.7), high blood pressure (RR2.3, 95%CI 1.2-4.1) and undernutrition (RR2.6, 95%CI 1.7-3.9). Nine patients had recurrent TB. Employment status remained unchanged, with 47.5% still unemployed 18-24 months later.

conclusionsTB survivors experienced substantial multimorbidity 18-24 months post-TB treatment. Health services must integrate long-term care strategies to address these ongoing health challenges.

Indexed as

Chinaemployment statushealth systemsmultimorbidityreal-time operational researchtuberculosis

Identifiers

PMID40365025
PMCPMC12068454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.